

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES  
EXCHANGE ACT OF 1934**

**September 2020**

Commission File Number: **001-39458**

**Medicenna Therapeutics Corp.**  
(Translation of registrant's name into English)

**2 Bloor St. W., 7th Floor**  
**Toronto, Ontario M4W 3E2, Canada**  
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.  
Form 20-F [  ]    Form 40-F [  ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [  ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [  ]

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**MEDICENNA THERAPEUTICS CORP.**

Date: September 9, 2020

By: /s/ Elizabeth Williams  
Name: Elizabeth Williams  
Title: Chief Financial Officer

---

## EXHIBIT INDEX

<u>Exhibit Number</u>	<u>Description</u>
<a href="#">99.1</a>	<a href="#">Press Release dated September 9, 2020</a>

## Medicenna to Present at Upcoming Investor Conferences in September

TORONTO and HOUSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (Nasdaq: MDNA) (TSX: MDNA), a clinical stage immuno-oncology company, today announced that Fahar Merchant, Ph.D., President and Chief Executive Officer of Medicenna, will present at the virtual H.C. Wainwright 22<sup>nd</sup> Annual Global Investment Conference 2020, as well as participate in a fireside chat at the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit. Both conferences are being held in September 2020. See below for more details.

### **Conferences Details:**

Event: H.C. Wainwright 22<sup>nd</sup> Annual Global Investment Conference 2020 (virtual)  
 Format: Presentation  
 Date: Wednesday, September 16<sup>TH</sup>  
 Time: 10:30 a.m. ET  
 Webcast: [Link](#)

Event: Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (virtual)  
 Format: Fireside Chat  
 Date: Tuesday, September 22<sup>nd</sup>  
 Time: 1:40 p.m. ET  
 Webcast: [Link](#)

Live webcasts of both events will be available in the investor relations section of Medicenna's website at <https://ir.medicenna.com/events-and-presentations>. After the live webcasts, each event will remain archived on Medicenna's website for approximately 90 days.

### **About Medicenna**

Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Cytokines™ (ECs) for the treatment of a broad range of cancers. Medicenna's long-acting IL2 Superkine asset, MDNA11, is potentially a best-in-class next-generation IL-2 with superior CD122 binding without CD25 affinity and therefore preferentially stimulating cancer killing effector T cells and NK cells when compared to competing IL-2 programs. It is anticipated that MDNA11 will be ready for the clinic in 2021. Medicenna's lead IL4-EC, MDNA55, has completed a Phase 2b clinical trial for recurrent glioblastoma (rGBM), the most common and uniformly fatal form of brain cancer. An End of Phase 2 meeting with the FDA is planned for 29<sup>th</sup> September 2020. MDNA55 has been studied in five clinical trials involving 132 patients, including 112 adults with rGBM. MDNA55 has demonstrated compelling efficacy and has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively. For more information, please visit [www.medicenna.com](http://www.medicenna.com).

*This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects", "believes" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements related to the future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the risks detailed in the annual information form of the Company dated May 14, 2020 and in other filings made by the Company with the applicable securities regulators from time to time.*

*The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect and that study results could change over time as the study is continuing to follow up all patients and new data are continually being received which could materially change study results. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements only as expressly required by Canadian securities law.*

Further Information

For further information about the Company please contact:

Elizabeth Williams, Chief Financial Officer, 416-648-5555, ewilliams@medicenna.com

## Investor Contact

For more investor information, please contact:

Dan Ferry, Managing Director, LifeSci Advisors, 617-430-7576, daniel@lifesciadvisors.com